Novartis is discontinuing the development of its drug Tasigna as initial therapy for patients with a rare form of stomach cancer because it is unlikely the drug will work better than Gleevec, the current standard of care.
WSJ.com: US Business, Wall Street Journal: Business
Mon, 04/11/2011 - 10:19am
Novartis is discontinuing the development of its drug Tasigna as initial therapy for patients with a rare form of stomach cancer because it is unlikely the drug will work better than Gleevec, the current standard of care.